FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034199647> ?p ?o ?g. }

• W2034199647 endingPage "685" @default.
• W2034199647 startingPage "679" @default.
• W2034199647 abstract "In this phase I study, we assessed the safety and feasibility of intravenous, autologous bone marrow (BM) cell therapy, without immunosuppressive preconditioning, in six patients with clinically definite, relapsing-progressive multiple sclerosis (MS). Assessment of efficacy was a secondary objective and employed clinical disability rating scales, multimodal evoked potential (MMEP) recordings, and magnetic resonance imaging (MRI) scans. Cells were harvested, filtered and infused intravenously in a day-case procedure that was well tolerated by patients and was not associated with any serious adverse events (AEs). Over a period of 12 months after the therapy, clinical disability scores showed either no change (Extended Disability Status Score, EDSS) or improvement (MS impact scale-29, MSIS-29), and MMEPs showed neurophysiological improvement. MRI scans did not show any significant changes over a post-therapy period of 3 months. The lack of serious adverse effects and the suggestion of a beneficial effect in this small sample of patients with progressive disease justify conducting a larger phase II/III study to make a fuller assessment of the efficacy of mobilization of autologous BM in patients with MS. Clinical Pharmacology & Therapeutics (2010) 87 6, 679–685. doi: 10.1038/clpt.2010.44" @default.
• W2034199647 created "2016-06-24" @default.
• W2034199647 creator A5000688172 @default.
• W2034199647 creator A5001902655 @default.
• W2034199647 creator A5011040789 @default.
• W2034199647 creator A5014925593 @default.
• W2034199647 creator A5023932918 @default.
• W2034199647 creator A5045336469 @default.
• W2034199647 creator A5053933321 @default.
• W2034199647 creator A5069064723 @default.
• W2034199647 creator A5078057490 @default.
• W2034199647 date "2010-05-05" @default.
• W2034199647 modified "2023-09-26" @default.
• W2034199647 title "Safety and Feasibility of Autologous Bone Marrow Cellular Therapy in Relapsing-Progressive Multiple Sclerosis" @default.
• W2034199647 cites W147684201 @default.
• W2034199647 cites W1924525408 @default.
• W2034199647 cites W1982495693 @default.
• W2034199647 cites W1983909073 @default.
• W2034199647 cites W1987270591 @default.
• W2034199647 cites W1989820252 @default.
• W2034199647 cites W1998538509 @default.
• W2034199647 cites W2000944968 @default.
• W2034199647 cites W2004800810 @default.
• W2034199647 cites W2007806661 @default.
• W2034199647 cites W2013353419 @default.
• W2034199647 cites W2015055389 @default.
• W2034199647 cites W2015074345 @default.
• W2034199647 cites W2016896159 @default.
• W2034199647 cites W2019181818 @default.
• W2034199647 cites W2023299094 @default.
• W2034199647 cites W2030412297 @default.
• W2034199647 cites W2031065339 @default.
• W2034199647 cites W2039533211 @default.
• W2034199647 cites W2044769151 @default.
• W2034199647 cites W2047062145 @default.
• W2034199647 cites W2051743031 @default.
• W2034199647 cites W2061276312 @default.
• W2034199647 cites W2075984099 @default.
• W2034199647 cites W2079705321 @default.
• W2034199647 cites W2080337955 @default.
• W2034199647 cites W2080431262 @default.
• W2034199647 cites W2085517533 @default.
• W2034199647 cites W2093248108 @default.
• W2034199647 cites W2103758700 @default.
• W2034199647 cites W2104878804 @default.
• W2034199647 cites W2106117542 @default.
• W2034199647 cites W2106126268 @default.
• W2034199647 cites W2110624941 @default.
• W2034199647 cites W2112165124 @default.
• W2034199647 cites W2120964352 @default.
• W2034199647 cites W2126737632 @default.
• W2034199647 cites W2142846397 @default.
• W2034199647 cites W2148728440 @default.
• W2034199647 cites W2150378783 @default.
• W2034199647 cites W2154093469 @default.
• W2034199647 cites W2155131183 @default.
• W2034199647 cites W2155758569 @default.
• W2034199647 cites W2171769546 @default.
• W2034199647 cites W2218047842 @default.
• W2034199647 cites W2414261370 @default.
• W2034199647 cites W4251403705 @default.
• W2034199647 doi "https://doi.org/10.1038/clpt.2010.44" @default.
• W2034199647 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20445531" @default.
• W2034199647 hasPublicationYear "2010" @default.
• W2034199647 type Work @default.
• W2034199647 sameAs 2034199647 @default.
• W2034199647 citedByCount "73" @default.
• W2034199647 countsByYear W20341996472012 @default.
• W2034199647 countsByYear W20341996472013 @default.
• W2034199647 countsByYear W20341996472014 @default.
• W2034199647 countsByYear W20341996472015 @default.
• W2034199647 countsByYear W20341996472016 @default.
• W2034199647 countsByYear W20341996472017 @default.
• W2034199647 countsByYear W20341996472018 @default.
• W2034199647 countsByYear W20341996472019 @default.
• W2034199647 countsByYear W20341996472020 @default.
• W2034199647 countsByYear W20341996472021 @default.
• W2034199647 countsByYear W20341996472022 @default.
• W2034199647 countsByYear W20341996472023 @default.
• W2034199647 crossrefType "journal-article" @default.
• W2034199647 hasAuthorship W2034199647A5000688172 @default.
• W2034199647 hasAuthorship W2034199647A5001902655 @default.
• W2034199647 hasAuthorship W2034199647A5011040789 @default.
• W2034199647 hasAuthorship W2034199647A5014925593 @default.
• W2034199647 hasAuthorship W2034199647A5023932918 @default.
• W2034199647 hasAuthorship W2034199647A5045336469 @default.
• W2034199647 hasAuthorship W2034199647A5053933321 @default.
• W2034199647 hasAuthorship W2034199647A5069064723 @default.
• W2034199647 hasAuthorship W2034199647A5078057490 @default.
• W2034199647 hasConcept C126322002 @default.
• W2034199647 hasConcept C126838900 @default.
• W2034199647 hasConcept C141071460 @default.
• W2034199647 hasConcept C143409427 @default.
• W2034199647 hasConcept C143998085 @default.
• W2034199647 hasConcept C197934379 @default.
• W2034199647 hasConcept C203014093 @default.
• W2034199647 hasConcept C2780007613 @default.
• W2034199647 hasConcept C2780640218 @default.

• next